TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20362695

Group type: EXPERIMENTAL
Intervention: Percutaneous liver biopsy
Number of subjects: 2740

Group type: EXPERIMENTAL
Intervention: Patients with platelet counts of 60,000/mm(3) or less
Number of subjects: 2740

Group type: EXPERIMENTAL
Intervention: Patients with international normalized ratio of 1.3 or greater
Number of subjects: 2740

Group type: EXPERIMENTAL
Intervention: Excluding subjects with platelet count of 60,000/mm(3) or less
Number of subjects: 2740

Group type: EXPERIMENTAL
Intervention: Operator experience, type of needle used, ultrasound guidance
Number of subjects: 2740

Group type: EXPERIMENTAL
Intervention: Persons with hepatitis C and advanced fibrosis
Number of subjects: 2740
Study: 20362723

Group type: EXPERIMENTAL
Intervention: EHR systems (30% EHR-only; 22% both EHR and paper)
Number of subjects: 15381

Group type: COMPARATOR
Intervention: Paper-only systems
Number of subjects: 15381

Group type: EXPERIMENTAL
Intervention: EHR systems
Number of subjects: 15381
Study: 20362722

Group type: EXPERIMENTAL
Intervention: AED plus CPR training
Number of subjects: 7001

Group type: COMPARATOR
Intervention: CPR training only
Number of subjects: 7001
Study: 20363090

Group type: EXPERIMENTAL
Intervention: Extended-release naltrexone (XR-NTX) 380 mg, intramuscular, with monthly medical management (MM)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Monthly medical management (MM)
Number of subjects: 72
Study: 20364383

Group type: EXPERIMENTAL
Intervention: Intraepidermal injection of autologous dissociated epidermal cell suspension
Number of subjects: 10
Study: 20368313

Group type: EXPERIMENTAL
Intervention: Glomerular filtration rate (GFR) reference values measured at inclusion and weekly for the first month using 12-hour urine specimens.
Number of subjects: 275
Study: 20368317

Group type: EXPERIMENTAL
Intervention: Clinical/otologic score including symptoms and tympanic-membrane examination
Number of subjects: 469

Group type: EXPERIMENTAL
Intervention: AOM total-severity index including symptoms and tympanic-membrane examination
Number of subjects: 469

Group type: COMPARATOR
Intervention: AOM severity-of-symptom scale based solely on symptoms
Number of subjects: 469
Study: 20368322

Group type: EXPERIMENTAL
Intervention: Caregivers with inadequate literacy
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Caregivers with adequate literacy
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Caregivers with limited literacy
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Caregivers with at least 50% correct math answers
Number of subjects: 200

Group type: COMPARATOR
Intervention: Caregivers who failed to answer at least 50% of math questions correctly
Number of subjects: 200
Study: 20368434

Group type: EXPERIMENTAL
Intervention: Decitabine (20 mg/m² i.v. over 1 h on days 1 to 10)
Number of subjects: 53
Study: 20368649

Group type: EXPERIMENTAL
Intervention: Magnetic resonance angiography
Number of subjects: 371

Group type: EXPERIMENTAL
Intervention: Magnetic resonance angiography and venography
Number of subjects: 371

Group type: EXPERIMENTAL
Intervention: Magnetic resonance angiography (including technically inadequate images)
Number of subjects: 371
Study: 20369375

Group type: EXPERIMENTAL
Intervention: Enzastaurin 500 mg/day
Number of subjects: 0
Study: 20370777

Group type: EXPERIMENTAL
Intervention: Early progression to shock within 72 hours
Number of subjects: 472

Group type: EXPERIMENTAL
Intervention: Progression to severe sepsis or shock within 72 hours
Number of subjects: 472
Study: 20372873

Group type: EXPERIMENTAL
Intervention: Low-dose growth hormone treatment (0.3 +/- 0.04 mg/day) for 24 weeks
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Low-dose growth hormone treatment (0.3 +/- 0.04 mg/day) for 48 weeks
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Low-dose growth hormone treatment (0.3 +/- 0.04 mg/day) for 24 and 48 weeks
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Low-dose growth hormone treatment (0.3 +/- 0.04 mg/day)
Number of subjects: 6
Study: 20374273

Group type: EXPERIMENTAL
Intervention: Chelated patients
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Patients with SCD
Number of subjects: 44

Group type: COMPARATOR
Intervention: Patients with TM
Number of subjects: 44
Study: 20375178

Group type: EXPERIMENTAL
Intervention: Preexcision urine AQP1 concentration in patients with clear cell or papillary cancer (n=32)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Preexcision urine ADFP concentration in patients with clear cell or papillary cancer (n=32)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Postnephrectomy urine AQP1 concentration in patients with clear cell or papillary cancer (n=25)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Postnephrectomy urine ADFP concentration in patients with clear cell or papillary cancer (n=25)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Correlation between tumor size and preexcision urine AQP1 concentration in patients with clear cell and papillary carcinoma
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Correlation between tumor size and preexcision urine ADFP concentration in patients with clear cell and papillary carcinoma
Number of subjects: 42
Study: 20375343

Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab injections
Number of subjects: 12
Study: 20375733

Group type: EXPERIMENTAL
Intervention: FAS
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: pFAS
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: ARND
Number of subjects: 78

Group type: COMPARATOR
Intervention: Control (pFAS and ARND)
Number of subjects: 78
Study: 20377408

Group type: EXPERIMENTAL
Intervention: Sputum samples from children with positive stool samples for Cryptosporidium
Number of subjects: 17

Group type: COMPARATOR
Intervention: Sputum samples from children with negative stool samples for Cryptosporidium
Number of subjects: 17

Group type: COMPARATOR
Intervention: Saliva samples from children tested for Cryptosporidium
Number of subjects: 17
Study: 20378407

Group type: EXPERIMENTAL
Intervention: Vorinostat 300 mg once daily
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Vorinostat 400 mg once daily
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Vorinostat (various doses)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Vorinostat
Number of subjects: 16
Study: 20378559

Group type: EXPERIMENTAL
Intervention: Acute painful episodes
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Serum amyloid A
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Apolipoprotein A-I
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Serum amyloid A/apolipoprotein A-I ratio
Number of subjects: 26
Study: 20378600

Group type: EXPERIMENTAL
Intervention: Expiratory flow limitation (EFL) determined via the negative expiratory pressure (NEP) method
Number of subjects: 448

Group type: EXPERIMENTAL
Intervention: Negative expiratory pressure (NEP) method
Number of subjects: 448

Group type: EXPERIMENTAL
Intervention: Ventilatory polygraphy (VP)
Number of subjects: 448
Study: 20378616

Group type: EXPERIMENTAL
Intervention: Ganirelix (GnRH antagonist)
Number of subjects: 1000

Group type: COMPARATOR
Intervention: GnRH agonist (buserelin)
Number of subjects: 1000
Study: 20378679

Group type: EXPERIMENTAL
Intervention: Home hip abductor strengthening program
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (participants without knee OA)
Number of subjects: 40
Study: 20378730

Group type: EXPERIMENTAL
Intervention: Isoniazid preventive therapy (IPT) - 6 months of open-label, daily, self-administered INH.
Number of subjects: 1762

Group type: COMPARATOR
Intervention: Antiretroviral therapy (ART) - received by 480 participants.
Number of subjects: 1762

Group type: COMPARATOR
Intervention: Alcohol use - defined by CAGE criteria.
Number of subjects: 1762

Group type: COMPARATOR
Intervention: Age greater than 35 years and presence of hepatitis B virus core antibody.
Number of subjects: 1762
Study: 20378927

Group type: EXPERIMENTAL
Intervention: Modified slow-release oral testosterone
Number of subjects: 16

Group type: COMPARATOR
Intervention: Immediate-release oral testosterone
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Oral testosterone with finasteride
Number of subjects: 16

Group type: COMPARATOR
Intervention: Oral testosterone without finasteride
Number of subjects: 16
Study: 20380712

Group type: EXPERIMENTAL
Intervention: de-novo CNI-free immunosuppression with basiliximab, mycophenolate sodium, prednisolone and everolimus
Number of subjects: 29
Study: 20382691

Group type: EXPERIMENTAL
Intervention: Group 2 (waist circumference 88-93 cm)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Group 3 (waist circumference 94-101 cm)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Group 4 (waist circumference 102 cm or greater)
Number of subjects: 42
Study: 20383216

Group type: EXPERIMENTAL
Intervention: Nonmyeloablative conditioning regimen for hematopoietic cell transplantation (HCT)
Number of subjects: 6
Study: 20384395

Group type: EXPERIMENTAL
Intervention: Propiverine 5, 10 and 15 mg twice daily for 14 days
Number of subjects: 25
Study: 20384962

Group type: EXPERIMENTAL
Intervention: Recombinant hepatitis B vaccine
Number of subjects: 222
Study: 20385792

Group type: EXPERIMENTAL
Intervention: Lenalidomide-bortezomib-dexamethasone combination therapy
Number of subjects: 66
Study: 20385942

Group type: EXPERIMENTAL
Intervention: Type 2 ROP
Number of subjects: 294

Group type: EXPERIMENTAL
Intervention: Type 2 ROP with examination in <7 days
Number of subjects: 294

Group type: EXPERIMENTAL
Intervention: Type 2 ROP that continued at first follow-up examination
Number of subjects: 294

Group type: EXPERIMENTAL
Intervention: Weekly examinations for type 2 ROP
Number of subjects: 294
Study: 20386074

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIg) therapy (2 g/kg)
Number of subjects: 17
Study: 20386909

Group type: EXPERIMENTAL
Intervention: MK-0457 (24-h continuous intravenous infusion at 64 mg/m(2)/h every 21 days)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: MK-0457 (100 mg oral dose administered 48 h prior to CIV infusion)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: MK-0457 (24-h continuous intravenous infusion)
Number of subjects: 27
Study: 20390419

Group type: EXPERIMENTAL
Intervention: TSU-68 at a dose of 200 mg bid
Number of subjects: 35
Study: 20391423

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIG) 400 mg/kg every 3 weeks from week 12 to week 24 of gestation
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIG)
Number of subjects: 20
Study: 20393117

Group type: EXPERIMENTAL
Intervention: SD-OCT
Number of subjects: 12

Group type: COMPARATOR
Intervention: CFP
Number of subjects: 12
Study: 20393132

Group type: EXPERIMENTAL
Intervention: Cytarabine combined with ATRA and idarubicin in the first and third consolidation courses for high-risk patients.
Number of subjects: 372

Group type: EXPERIMENTAL
Intervention: Reduced dose of mitoxantrone for the second consolidation course for low- and intermediate-risk patients.
Number of subjects: 372

Group type: COMPARATOR
Intervention: LPA2005 trial (new trial)
Number of subjects: 372
Study: 20393336

Group type: EXPERIMENTAL
Intervention: Single-port appendectomy (SA)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Three-port appendectomy (TA)
Number of subjects: 72
Study: 20394026

Group type: EXPERIMENTAL
Intervention: Continuous insulin infusion (CII)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Continuous insulin infusion (CII) with oral intake
Number of subjects: 200
Study: 20394321

Group type: COMPARATOR
Intervention: Sleep related breathing disorders (SRBD) diagnosed by apnea-hypopnea index (AHI) > 15 events/h, with 445 subjects (53%) diagnosed, and 167 subjects (37%) with AHI > 30.
Number of subjects: 827

Group type: COMPARATOR
Intervention: Subjects with AHI > 30 (severe SRBD).
Number of subjects: 827

Group type: COMPARATOR
Intervention: Subjects with AHI ≤ 15 (no SRBD).
Number of subjects: 827
Study: 20394897

Group type: EXPERIMENTAL
Intervention: Strain-encoded cardiac magnetic resonance (SENC)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Cine imaging
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: SENC
Number of subjects: 80
Study: 20395557

Group type: EXPERIMENTAL
Intervention: let-7d antagomir
Number of subjects: 20
Study: 20395855

Group type: EXPERIMENTAL
Intervention: Components separation technique for hernia repair
Number of subjects: 19
Study: 20398812

Group type: EXPERIMENTAL
Intervention: Dermicol-P35 27G, 30G, or both
Number of subjects: 30
Study: 20398872

Group type: EXPERIMENTAL
Intervention: JACTAX HD paclitaxel-eluting stent
Number of subjects: 103
Study: 20398925

Group type: EXPERIMENTAL
Intervention: MDV3100 30 mg
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: MDV3100 60 mg
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: MDV3100 240 mg
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: MDV3100 (various doses)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: MDV3100 (60 mg to 480 mg)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: MDV3100
Number of subjects: 140
Study: 20398959

Group type: EXPERIMENTAL
Intervention: Triple combination cream (hydroquinone 4%, tretinoin 0.05%, fluocinolone acetonide 0.01%) daily for 12 weeks, then maintenance therapy twice per week for 12 weeks if clear or almost clear (cohort B)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Triple combination cream (hydroquinone 4%, tretinoin 0.05%, fluocinolone acetonide 0.01%) daily for 24 weeks (cohort A)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Triple combination cream (hydroquinone 4%, tretinoin 0.05%, fluocinolone acetonide 0.01%) daily for 12 weeks, then returned to daily dosing after relapse during maintenance (cohort C)
Number of subjects: 70
Study: 20400682

Group type: EXPERIMENTAL
Intervention: WT1 peptide vaccine (4 peptides, 200 microg each) with immune adjuvants, administered over 12 weeks (6 vaccinations)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: WT1 peptide vaccine
Number of subjects: 9
Study: 20400762

Group type: EXPERIMENTAL
Intervention: Enoxaparin for up to 8 days
Number of subjects: 20275

Group type: COMPARATOR
Intervention: Unfractionated heparin (UFH) for 48 h
Number of subjects: 20275

Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 20275

Group type: COMPARATOR
Intervention: UFH
Number of subjects: 20275
Study: 20402989

Group type: EXPERIMENTAL
Intervention: Motivational Interview with Personalized Feedback (MI)
Number of subjects: 172

Group type: COMPARATOR
Intervention: Feedback Only (FO)
Number of subjects: 172
Study: 20403849

Group type: EXPERIMENTAL
Intervention: Endoscopic sinus surgery
Number of subjects: 102
Study: 20403855

Group type: EXPERIMENTAL
Intervention: Robotic primary surgery
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Robotic salvage surgery
Number of subjects: 36

Group type: COMPARATOR
Intervention: Open salvage surgery
Number of subjects: 36
Study: 20403857

Group type: EXPERIMENTAL
Intervention: Drug-induced sleep endoscopy with intravenous propofol infusion
Number of subjects: 108
Study: 20404380

Group type: EXPERIMENTAL
Intervention: Cerebral MRI with angiography performed up to 7 days after admission and before any surgical intervention.
Number of subjects: 130
Study: 20406267

Group type: EXPERIMENTAL
Intervention: APOE genotype (allele ∗2)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: APOE genotype (allele ∗4)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: APOE genotype (∗3∗3)
Number of subjects: 25
Study: 20407111

Group type: EXPERIMENTAL
Intervention: MB stent implantation
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Preintervention % diameter stenosis of the SB
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: MB minimum lumen diameter located distal to the SB ostium
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Patients with > or =75% stenosis and Thrombolysis In Myocardial Infarction grade 3 flow in the SB
Number of subjects: 77
Study: 20407116

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 20408846

Group type: EXPERIMENTAL
Intervention: ofatumumab (4 weekly infusions)
Number of subjects: 33
Study: 20409549

Group type: EXPERIMENTAL
Intervention: n-3 PUFA supplementation
Number of subjects: 450
Study: 20409626

Group type: EXPERIMENTAL
Intervention: Lubo Collar
Number of subjects: 30
Study: 20410100

Group type: EXPERIMENTAL
Intervention: SNPs in apolipoprotein J (APOJ)
Number of subjects: 761

Group type: EXPERIMENTAL
Intervention: SNPs in lipoprotein lipase (LPL)
Number of subjects: 761

Group type: EXPERIMENTAL
Intervention: SNPs in tumor necrosis factor receptor superfamily member 10b (TNFRSF10B)
Number of subjects: 761

Group type: EXPERIMENTAL
Intervention: Quantitative genetic analyses
Number of subjects: 761

Group type: EXPERIMENTAL
Intervention: Genome-wide scan for plasma fatty acids
Number of subjects: 761
Study: 20412178

Group type: EXPERIMENTAL
Intervention: Rifaximin 600 mg/d for 14 days
Number of subjects: 210

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 210
Study: 20413029

Group type: EXPERIMENTAL
Intervention: Combined HF device diagnostics (positive criteria: long atrial fibrillation duration, rapid ventricular rate during atrial fibrillation, high fluid index, low patient activity, abnormal autonomics, notable device therapy, or very high fluid index)
Number of subjects: 694

Group type: EXPERIMENTAL
Intervention: Combined HF device diagnostics (positive criteria)
Number of subjects: 694
Study: 20413039

Group type: EXPERIMENTAL
Intervention: Metabolic syndrome (MetS)
Number of subjects: 272
Study: 20413436

Group type: EXPERIMENTAL
Intervention: Nonperinatal patients (symptomatic beyond 1 month)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Perinatal patients
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Nonperinatal patients
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Corticomedullary involvement on HR-USG
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Medullary involvement only
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Children with enlarged kidneys
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Patients with medullary-only abnormalities
Number of subjects: 73
Study: 20413540

Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation (PR)
Number of subjects: 316

Group type: EXPERIMENTAL
Intervention: Baseline 6MWD
Number of subjects: 316

Group type: EXPERIMENTAL
Intervention: MRC score
Number of subjects: 316

Group type: EXPERIMENTAL
Intervention: Arterial carbon dioxide tension
Number of subjects: 316

Group type: EXPERIMENTAL
Intervention: Presence of osteoporosis
Number of subjects: 316
Study: 20413658

Group type: EXPERIMENTAL
Intervention: WT1 mutations
Number of subjects: 842

Group type: COMPARATOR
Intervention: No WT1 mutations
Number of subjects: 842

Group type: EXPERIMENTAL
Intervention: WT1 mutations without FLT3/ITD
Number of subjects: 842

Group type: COMPARATOR
Intervention: Wild type for both mutations
Number of subjects: 842
Study: 20413687

Group type: EXPERIMENTAL
Intervention: 4SC-101 (300 mg/kg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: CYC (30 mg/kg/week, i.p.)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 4SC-101 (30 mg/kg, 100 mg/kg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 0
Study: 20413733

Group type: EXPERIMENTAL
Intervention: Simvastatin treatment with LDLR haplotype 5 (LDLR L5) in blacks
Number of subjects: 944

Group type: EXPERIMENTAL
Intervention: Simvastatin treatment with combined LDLR L5 and HMGCR haplotypes in blacks
Number of subjects: 944

Group type: EXPERIMENTAL
Intervention: Simvastatin treatment measuring LDL receptor surface expression
Number of subjects: 944
Study: 20418368

Group type: EXPERIMENTAL
Intervention: Exercise Doppler echocardiography (EDE)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Cardiopulmonary exercise testing (CPET)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Right-sided heart catheterization (RHC)
Number of subjects: 52

Group type: COMPARATOR
Intervention: EDE vs RHC
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: EDE
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: EDE + CPET
Number of subjects: 52
Study: 20418798

Group type: EXPERIMENTAL
Intervention: CD4 count criteria for initiating antiretroviral therapy
Number of subjects: 446

Group type: EXPERIMENTAL
Intervention: Current CD4 count criteria
Number of subjects: 446
Study: 20420675

Group type: EXPERIMENTAL
Intervention: Exposure to organic or inorganic allergenic or irritant compounds
Number of subjects: 250

Group type: COMPARATOR
Intervention: No specific occupational exposure (control group)
Number of subjects: 250
Study: 20420716

Group type: EXPERIMENTAL
Intervention: Experimental intervention
Number of subjects: 58

Group type: COMPARATOR
Intervention: Treatment as usual (Control)
Number of subjects: 58
Study: 20421061

Group type: EXPERIMENTAL
Intervention: Cytokine analysis for IL-2, -8, -10, and granulocyte macrophage-colony stimulating factor in infected patients.
Number of subjects: 1655

Group type: EXPERIMENTAL
Intervention: Cytokine analysis for IL-6, -8, and IL-10 in noninfected nontrauma patients.
Number of subjects: 1655

Group type: EXPERIMENTAL
Intervention: Cytokine analysis for IL-4, -6, -8, and TNF-alpha in trauma patients.
Number of subjects: 1655

Group type: EXPERIMENTAL
Intervention: IL-4 in trauma patients.
Number of subjects: 1655

Group type: EXPERIMENTAL
Intervention: IL-8 in nontrauma, noninfected patients.
Number of subjects: 1655

Group type: EXPERIMENTAL
Intervention: Cytokine analysis in infected patients.
Number of subjects: 1655
Study: 20421274

Group type: EXPERIMENTAL
Intervention: Deferasirox
Number of subjects: 0
Study: 20421452

Group type: EXPERIMENTAL
Intervention: Deferasirox (30 to 40 mg/kg per day)
Number of subjects: 28
Study: 20421455

Group type: EXPERIMENTAL
Intervention: IDH2 mutations present (12.1% of CN-AML patients)
Number of subjects: 272

Group type: COMPARATOR
Intervention: IDH2 mutations absent (majority of CN-AML patients)
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: IDH2 mutations in AML patients with aberrant karyotypes (n = 130)
Number of subjects: 272
Study: 20422738

Group type: EXPERIMENTAL
Intervention: Perindopril and indapamide
Number of subjects: 11140

Group type: EXPERIMENTAL
Intervention: Perindopril-indapamide and gliclazide MR-based regimen
Number of subjects: 11140

Group type: EXPERIMENTAL
Intervention: Perindopril and indapamide and gliclazide-MR-based regimen
Number of subjects: 11140
Study: 20424554

Group type: EXPERIMENTAL
Intervention: IL-6 -572C/G polymorphism
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: IL-10 -1082A/G polymorphism
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: TNF-alpha -308G/A polymorphism
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Ratio of circulating concentrations of IL-10/IL-6
Number of subjects: 212

Group type: COMPARATOR
Intervention: Control group (patients without acute lung injury)
Number of subjects: 212